Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Renin inhibitors

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Renin inhibitors. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2008-007881-45 Sponsor Protocol Number: SPP100ANL02T Start Date*: 2009-03-12
    Sponsor Name:University Medical Center Groningen
    Full Title: A double-blind, placebo-controlled, randomized trial investigating the safety and efficacy of Additive Renin Inhibition with Aliskiren on renal blood flow and Neurohormonal Activation in patients w...
    Medical condition: Patients with chronic heart failure and reduced glomerular filtration rate.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10038443 Renal failure and impairment HLT
    9.1 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000452-14 Sponsor Protocol Number: FARM537JNE Start Date*: 2007-08-29
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Long term impact of renin angiotensin system RAS inhibition on cardiorenal outcomes. A randomized controlled trial of cardio-renal effects of RAS inhibition in patients with cardio-renal risk. A...
    Medical condition: Patients with one or more cardiovascular risk factors and microalbuminuria, diabetic or not diabetic.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027525 Microalbuminuria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007149-30 Sponsor Protocol Number: 4500 Start Date*: 2009-01-14
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and University of Cambridge [...]
    1. Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
    2. Cambridge Clinical Trials Unit
    Full Title: Optimal Treatment of Drug Resistant Hypertension
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    15.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001595-15 Sponsor Protocol Number: 270389-010520 Start Date*: 2020-06-23
    Sponsor Name:Henrik Birn
    Full Title: The Measures to Optimize RAAS-blockade in Patients with Hyperkalemia and Chronic Kidney Disease
    Medical condition: Chronic kidney disease with albuminuria
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10020647 Hyperkalemia LLT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-001929-24 Sponsor Protocol Number: 1392-H-199 Start Date*: 2011-09-19
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital 12 de Octubre
    Full Title: Randomised, open-label, crossover clinical trial to evaluate the antiproteinuric effect of three different types of diuretics (hydrochlorothiazide, amiloride and spironolactone) in patients with ch...
    Medical condition: Chronic proteinuric nephropathies
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004192-37 Sponsor Protocol Number: CRO1749 Start Date*: 2012-04-24
    Sponsor Name:Joint Research Compliance Office, Imperial College
    Full Title: Hellenic Anglo Research into Morning Or Night antihypertensive drug deliverY trial.
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10047065 - Vascular disorders 10020772 Hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001544-26 Sponsor Protocol Number: RASCOVID-19 Start Date*: 2020-04-22
    Sponsor Name:Center for Clinical Metabolic Research, Gentofte Hospital
    Full Title: Effects of discontinuing renin-angiotensin system inhibitors in patients with and without COVID-19
    Medical condition: Coronavirus disease 2019 (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10005747 Blood pressure high LLT
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002262-12 Sponsor Protocol Number: DAPA-OB Start Date*: 2021-05-17
    Sponsor Name:Hospital Universitari Germans Trias i Pujol
    Full Title: "Effect of dapagliflozin on glomerular hyperfiltration in nondiabetic obese patients with or without treatment with ACEIs". Pilot clinical trial of efficacy, low level of intervention, unicentric, ...
    Medical condition: This study aims to demonstrate the hypothesis that treatment with dapagliflozin 10mg lowers in at least 10-20% of measured glomerular filtration rate (mGFR) in non-diabetic obese patients with glom...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-004042-42 Sponsor Protocol Number: DEER Start Date*: 2014-06-19
    Sponsor Name:King’s College London [...]
    1. King’s College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: A study to investigate the potential renoprotective role of sodium-glucose transporter-2 (SGLT-2) antagonist Dapagliflozin in Type 2 diabetic patients with diabetic nephropathy
    Medical condition: Diabetic Nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10061835 Diabetic nephropathy PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-002396-18 Sponsor Protocol Number: 2015-602295-02 Start Date*: 2015-11-30
    Sponsor Name:Ethicare GmbH
    Full Title: ORODISPERSIBLE MINITABLETS OF ENALAPRIL IN YOUNG CHILDREN WITH HEART FAILURE DUE TO CONGENITAL HEART DISEASE
    Medical condition: Heart Failure due to Congenital Heart Disease
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10010495 Congenital heart disease NOS LLT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Prematurely Ended) NL (Ongoing) AT (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004152-10 Sponsor Protocol Number: EMPATHY Start Date*: 2020-01-30
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Evaluating the Short-Term Renal and Systemic Effects of SGLT2 Inhibition in Non-Diabetic Patients at Risk of Accelerated GFR Decline Because of Glomerular Hyperfiltration: a sequential OFF-ON-OFF S...
    Medical condition: Obesity Renal chronic disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    21.1 100000004857 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017336-40 Sponsor Protocol Number: 1235.33 Start Date*: 2010-04-26
    Sponsor Name:Boehringer Ingelheim BV
    Full Title: Prospective, open label TElmisartan/AMlodipine single pill STudy to Assess the efficacy in patients with essential hypertension who are not controlled on RAASi mono-therapy being switched.
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    12.1 10005757 Blood pressure systolic abnormal LLT
    12.1 10005728 Blood pressure abnormal LLT
    12.1 10005736 Blood pressure diastolic abnormal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002785-31 Sponsor Protocol Number: RLY5016-206p Start Date*: 2017-08-03
    Sponsor Name:Vifor Pharma, Inc.
    Full Title: A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age with...
    Medical condition: Chronic Kidney Disease and Hyperkalemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10020647 Hyperkalemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) BG (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-006579-41 Sponsor Protocol Number: ANG3070-CKD-201 Start Date*: 2022-03-07
    Sponsor Name:Angion Biomedica Corp.
    Full Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria
    Medical condition: Primary glomerular disease and persistent proteinuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10037032 Proteinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002299-28 Sponsor Protocol Number: 20110203 Start Date*: 2017-01-17
    Sponsor Name:Amgen Inc
    Full Title: A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Omecamtiv Mecarbil on Mortality and Morbidity in Subjects With Chronic Heart Failure With Redu...
    Medical condition: Chronic Heart Failure With Reduced Ejection Fraction
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) SE (Completed) CZ (Completed) ES (Completed) HU (Completed) NL (Completed) GB (Completed) PT (Completed) PL (Completed) AT (Completed) SK (Completed) BG (Completed) LT (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002636-25 Sponsor Protocol Number: RG_13-013NS Start Date*: 2013-09-11
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease
    Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000947-88 Sponsor Protocol Number: 09A502 Start Date*: 2008-02-18
    Sponsor Name:ISTITUTO AUXOLOGICO ITALIANO
    Full Title: Therapeutic Strategies of Prevention of Diabetes and Hypertension in Subjects with Metabolic Syndrome and High-Normal Blood Pressure.
    Medical condition: Hypertension, diabetes mellitus.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10007541 SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000225-30 Sponsor Protocol Number: DMA-Clin-199-2013-001 Start Date*: 2013-04-12
    Sponsor Name:DiaMedica USA Inc.
    Full Title: A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS...
    Medical condition: Diabetes Mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001363-31 Sponsor Protocol Number: M05-741 Start Date*: 2007-05-28
    Sponsor Name:Abbott GmbH & Co KG
    Full Title: Estudio VITAL- Estudio del activador del receptor de la vitamina D selectivo (Paricalcitol) para la reducción de la albúmina: Estudio multicéntrico de fase II, prospectivo aleatorizado, a doble cie...
    Medical condition: Nefropatía diabética Tipo 2. Type 2 diabetic nephropathy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) PT (Completed) GR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-004174-64 Sponsor Protocol Number: DMX-200-301 Start Date*: 2022-03-08
    Sponsor Name:Dimerix Bioscience Pty Ltd
    Full Title: A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving...
    Medical condition: Focal segmental glomerulosclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    21.1 10038359 - Renal and urinary disorders 10016832 Focal & segmental glomerulosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 05:29:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA